Anti-obesity Effect of Dextromethorphan in High Fat Diet Induced Obesity in Rats
Keywords:
Obesity, Dextromethorphan, Orlistat, BMIAbstract
Obesity is associated with significant comorbidities. Treatment options for obesity include only few drugs. Several hormones and receptors play key role in pathogenesis of obesity like NMDA, PPAR-gamma, leptin, pro-opiomelanocortin (POMC) and others. To check anti-obesity effect of Dextromethorphan (DXM) in high fat diet (HFD) induced obesity. Male Wistar albino rats (BW- 250-350 grams) were divided into 5 groups. Group 1 (Normal control) was fed with standard pellets. All the remaining groups were fed with High fat diet (HFD) to induce obesity. Group 2 served as HFD control. Group 3 (standard), group 4 (DXM-P) and group 5 (DXM-T) received orlistat (10 mg/kg, day 49 to 84), dextromethorphan (DXM) (15 mg/kg, day 0 to 84) and DXM (15 mg/kg, day 49 to 84) respectively. All the drugs were administered orally. Food intake (daily), water intake (daily) and body weight (weekly) were measured. Serum cholesterol (TC), Serum triglyceride (TG), HDL and LDL; OGTT, BMI, white adipose tissue (WAT) mass were measured. No significant difference was observed in food intake, BMI, TC, LDL and HDL between disease and treatment groups. BMI was significantly increased in HFD group and decreased in orlistat and DXM-P group. WAT mass and blood glucose were significantly decreased in all treatment groups as compared to HFD control. Administration of dextromethorphan in both the groups improved body weight, BMI (only DEX-P), WAT mass, glucose tolerance and serum TG. Dextromethorphan can be further studied for further development in treatment of obesity.
References
Nuttall FQ. Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutr Today. 2015; 50(3):117-128. doi: 10.1097/NT.0000000000000092.
Gjermeni E, Kirstein AS, Kolbig F, Kirchhof M, Bundalian L, Katzmann JL, Laufs U, Blüher M, Garten A, Le Duc D. Obesity-An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances. Biomolecules. 2021; 11(10):1426. doi: 10.3390/biom11101426.
Wright SM, Aronne LJ. Causes of obesity. Abdom Imaging. 2012; 37(5): 730-2. doi: 10.1007/s00261-012-9862-x.
Lobstein T, Jewell J. What is a "high" prevalence of obesity? Two rapid reviews and a proposed set of thresholds for classifying prevalence levels. Obes Rev. 2022; 23(2): e13363. doi: 10.1111/obr.13363.
Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R and Mantzorosc CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. eClinical Medicine. 2023; 58: 101882. doi: https://doi.org/10.1016/j.eclinm.2023.10188.
Cornier MA. A review of current guidelines for the treatment of obesity. Am J Manag Care. 2022; 28 (15 Suppl): S288-S296. doi: 10.37765/ajmc.2022.89292.
Gérard, P. Gut microbiota and obesity. Cell Mol Life Sci. 2016; 73: 147–162. doi: https://doi.org/10.1007/s00018-015-2061-5.
Oussaada SM, van Galen KA, Cooiman MI, Kleinendorst L, Hazebroek EJ, van Haelst MM, Ter Horst KW, Serlie MJ. The pathogenesis of obesity.
Metabolism. 2019; 92: 26-36. doi: 10.1016/j.metabol.2018.12.012.
Farhadipour M, Depoortere I. The Function of Gastrointestinal Hormones in Obesity-Implications for the Regulation of Energy Intake. Nutrients. 2021; 13(6): 1839. doi: 10.3390/nu13061839.
Wren AM. Gut and hormones and obesity. Front Horm Res. 2008; 36:165-181. doi: 10.1159/000115364.
Huang XT, Yang JX, Wang Z, Zhang CY, Luo ZQ, Liu W, Tang SY. Activation of N-methyl-D-aspartate receptor regulates insulin sensitivity and lipid metabolism. Theranostics. 2021; 11(5): 2247-2262. doi: 10.7150/thno.51666.
Jung TW, Hwang EJ, Pyun DH, Kim TJ, Lee HJ, Abd El-Aty AM, Bang JS, Kim HC, Jeong JH. 3-hydroxymorphinan enhances mitochondrial biogenesis and adipocyte browning through AMPK-dependent pathway. Biochem Biophys Res Commun. 2021; 577:17-23. doi: 10.1016/j.bbrc.2021.08.083.
Woods SC, Seeley RJ, Rushing PA, D'Alessio D, Tso P. A controlled high-fat diet induces an obese syndrome in rats. J Nutr. 2003; 133(4):1081-7. doi: 10.1093/jn/133.4.1081.
Saaristo TE, Barengo NC, Korpi-Hyövälti E, Oksa H, Puolijoki H, Saltevo JT, Vanhala M, Sundvall J, Saarikoski L, Peltonen M, Tuomilehto J. High prevalence of obesity, central obesity and abnormal glucose tolerance in the middle-aged Finnish population. BMC Public Health. 2008; 8:423. doi: 10.1186/1471-2458-8-423.
Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, Savoye M, Rieger V, Taksali S, Barbetta G, Sherwin RS, Caprio S. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 2002; 346(11):802-10. doi: 10.1056/NEJMoa012578.
Gerlini R, Berti L, Darr J, Lassi M, Brandmaier S, Fritsche L, Scheid F, Böhm A, Königsrainer A, Grallert H, Häring HU, Hrabě de Angelis M, Staiger H, Teperino R. Glucose tolerance and insulin sensitivity define adipocyte transcriptional programs in human obesity. Mol Metab. 2018 Dec;18:42-50. doi: 10.1016/j.molmet.2018.09.004.
Millington GW. The role of proopiomelanocortin (POMC) neurones in feeding behaviour. Nutr Metab (Lond). 2007; 4:18. doi: 10.1186/1743-7075-4-18.
Baldini G, Phelan KD. The melanocortin pathway and control of appetite-progress and therapeutic implications. J Endocrinol. 2019; 241(1): R1-R33. doi: 10.1530/JOE-18-0596.
Published
Abstract Display: 74 
PDF Downloads: 40 How to Cite
Issue
Section
Copyright (c) 2023 Shah Palak, Paregi Kanti, Patel Nimisha, Deshpande Shrikalp (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
